The deal will give Actavis access to three generic drug products – ciprofloxacin hydrochloride ophthalmic solution, levofloxacin ophthalmic solution and lidocaine hydrochloride jelly. The agreement also includes an originator product, Emla (lidocaine/prilocaine topical cream), and an undisclosed product under development.

The sale has come about as a result of, and is contingent upon, generic eye-drug maker Akorn’s acquisition of US specialty pharmaceutical business Hi-Tech [1].

The purchase of the five products is expected to complement the ‘expanding portfolio of topical and ophthalmic generic products’ for Actavis.

Related articles

Actavis buys Thai generics company

Actavis to acquire speciality drug maker Forest Labs

Reference

1.   GaBI Online - Generics and Biosimilars Initiative. Akorn to buy Hi-Tech Pharmacal for US$640 million [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 May 2]. Available from: www.gabionline.net/Pharma-News/Akorn-to-buy-Hi-Tech-Pharmacal-for-US-640-million

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.